Similarly, a candidate circulating CD4+ “cytotoxic” T-cell subset (GrB+PD-1+ with EM phenotype) has been identified in cHL patients, particularly in the R/R setting. This evidence concerns the gene CD4 and classic Hodgkin lymphoma.